Next Article in Journal
The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas—A Meta-Analysis and Systematic Review of the Literature
Previous Article in Journal
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
Previous Article in Special Issue
Autologous Transplantation for Older Adults with AML
Review

Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia

1
Division of Hematology, Cardarelli Hospital, 80128 Napoli, Italy
2
Department of Medicine, Hematology and Clinical Immunology Unit, University of Padua, 35153 Padua, Italy
3
Division of Hematology, Spedali Civili, 25123 Brescia, Italy
*
Author to whom correspondence should be addressed.
Received: 22 January 2019 / Revised: 5 February 2019 / Accepted: 10 February 2019 / Published: 14 February 2019
(This article belongs to the Special Issue Treatment of Older Adults with Acute Myeloid Leukemia)
Considerable progress has been made in the treatment of acute myeloid leukemia (AML). However, current therapeutic results are still unsatisfactory in untreated high-risk patients and poorer in those with primary refractory or relapsed disease. In older patients, reluctance by clinicians to treat unfit patients, higher AML cell resistance related to more frequent adverse karyotype and/or precedent myelodysplastic syndrome, and preferential involvement of chemorefractory early hemopoietic precursors in the pathogenesis of the disease further account for poor prognosis, with median survival lower than six months. A general agreement exists concerning the administration of aggressive salvage therapy in young adults followed by allogeneic stem cell transplantation; on the contrary, different therapeutic approaches varying in intensity, from conventional salvage chemotherapy based on intermediate–high-dose cytarabine to best supportive care, are currently considered in the relapsed, older AML patient population. Either patients’ characteristics or physicians’ attitudes count toward the process of clinical decision making. In addition, several new drugs with clinical activity described as “promising” in uncontrolled single-arm studies failed to improve long-term outcomes when tested in larger randomized clinical trials. Recently, new agents have been approved and are expected to consistently improve the clinical outcome for selected genomic subgroups, and research is in progress in other molecular settings. While relapsed AML remains a tremendous challenge to both patients and clinicians, knowledge of the molecular pathogenesis of the disease is fast in progress, potentially leading to personalized therapy in most patients. View Full-Text
Keywords: acute myeloid leukemia; older patients; relapse; new drugs acute myeloid leukemia; older patients; relapse; new drugs
Show Figures

Figure 1

MDPI and ACS Style

Ferrara, F.; Lessi, F.; Vitagliano, O.; Birkenghi, E.; Rossi, G. Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia. Cancers 2019, 11, 224. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11020224

AMA Style

Ferrara F, Lessi F, Vitagliano O, Birkenghi E, Rossi G. Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia. Cancers. 2019; 11(2):224. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11020224

Chicago/Turabian Style

Ferrara, Felicetto, Federica Lessi, Orsola Vitagliano, Erika Birkenghi, and Giuseppe Rossi. 2019. "Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia" Cancers 11, no. 2: 224. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11020224

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop